紫杉醇涂层球囊治疗下肢动脉疾病:BIOLUX P-III全球注册全人群队列12个月结果
BIOLUX P-III为国际前瞻性观察性注册研究,纳入700例患者863处病变,评估Passeo-18 Lux药物涂层球囊在真实世界中的安全性和性能。全人群6个月和12个月免于主要不良事件率分别为94.0%和89.5%,12个月免于临床驱动靶病变血运重建率为93.1%,无器械或手术相关死亡。
要点
- 全人群12个月免于MAE为89.5%,免于临床驱动TLR为93.1%。
- 股腘段病变12个月免于MAE为91.2%,免于TLR为93.9%。
- 支架内再狭窄亚组12个月免于MAE为88.0%,免于TLR为89.4%。
核心结论
- 在真实世界患者人群中,Passeo-18 Lux药物涂层球囊治疗下肢动脉粥样硬化性病变的安全性和性能得以维持,12个月性能结局良好且并发症率低。
研究设计与样本
- BIOLUX P-III为国际前瞻性观察性注册研究(NCT02276313),在欧洲、亚洲和澳大利亚41个中心开展,随访至6、12和24个月。
- 全人群队列纳入700例患者(平均年龄70.0±10.2岁,男性439例)共863处病变,其中糖尿病330例(47.1%),慢性肢体威胁性缺血234例(37.7%)。
- 79.3%的病变位于股腘段,645处(74.9%)病变钙化,99处(11.5%)为支架内再狭窄,平均病变长度84.7±73.3 mm。
主要发现
- 全人群6个月和12个月免于MAE率分别为94.0%和89.5%;股腘段组分别为95.0%和91.2%;ISR亚组分别为95.3%和88.0%。
- 全人群12个月免于临床驱动TLR率为93.1%,股腘段病变为93.9%,ISR病变为89.4%。
- 全人群全因死亡率为6.1%,股腘段和ISR亚组均为5.9%;截至12个月无器械或手术相关死亡。
- 12个月时所有亚组中超过80%的患者Rutherford分级改善。
关键数值与推荐
- 主要临床终点为6个月内主要不良事件(MAE),包括30天内器械和手术相关死亡、重大目标肢体截肢和临床驱动靶病变血运重建(TLR)的复合终点。
- 主要性能终点为12个月内临床驱动TLR。
临床怎么用
- 该真实世界注册数据支持Passeo-18 Lux药物涂层球囊用于下肢动脉粥样硬化性病变(包括股腘段和ISR)的治疗,12个月安全性和性能结局良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To further investigate the safety and performance of the Passeo-18 Lux drug-coated balloon (DCB) for the treatment of atherosclerotic infrainguinal disease under real-world conditions. Materials and Methods: BIOLUX P-III is an international, prospective, observational registry (ClinicalTrials.gov identifier NCT02276313) conducted at 41 centers in Europe, Asia, and Australia with follow-up visits at 6, 12, and 24 months. Of 700 patients (mean age 70.0±10.2 years; 439 men) with 863 lesions in the all-comers cohort, 330 (47.1%) patients had diabetes and 234 (37.7%) had chronic limb-threatening ischemia. The majority (79.3%) of lesions were in the femoropopliteal segment; of all lesions, 645 (74.9%) were calcified and 99 (11.5%) had in-stent restenosis (ISR). The mean lesion length was 84.7±73.3 mm. The primary clinical endpoint was major adverse events (MAEs) within 6 months, a composite of device- and procedure-related mortality through 30 days, major target limb amputation, and clinically-driven target lesion revascularization (TLR). The primary performance endpoint was clinically-driven TLR within 12 months. Results: At 6 and 12 months, freedom from MAEs was 94.0% and 89.5% in the all-comers cohort: 95.0% and 91.2% in the femoropopliteal group and 95.3% and 88.0% in the ISR subgroup, respectively. Freedom from clinically-driven TLR at 12 months was 93.1% in the all-comers cohort, 93.9% in the femoropopliteal lesions, and 89.4% for ISR lesions. All-cause mortality was 6.1% in the all-comers cohort: 5.9% in both the femoropopliteal and ISR subgroups. There were no device- or procedure-related deaths at up to 12 months. The Rutherford category improved in >80% of all subgroups at 12 months. Conclusion: In a real-world patient population, the safety and performance of the Passeo-18 Lux DCB for the treatment of atherosclerotic infrainguinal lesions are maintained, with good performance outcomes and low complication rates at 12 months.
引用
- Tepe G, Zeller T, Moscovic M, et al. Paclitaxel-Coated Balloon for the Treatment of Infrainguinal Disease: 12-Month Outcomes in the All-Comers Cohort of BIOLUX P-III Global Registry. J Endovasc Ther. 2020. PMID: 31989855. doi:10.1177/1526602819898804
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。